$97.9
+6.21
(+6.77%)▲
Gilead Sciences, Inc. is a biopharmaceutical company that develops innovative treatments for life-threatening diseases.
3.37%
Downside
Day's Volatility :3.47%
Upside
0.1%
36.6%
Downside
52 Weeks Volatility :36.87%
Upside
0.43%
Period | Gilead Sciences Inc. | |
---|---|---|
3 Months | 29.51% | |
6 Months | 50.8% | |
1 Year | 25.67% | |
3 Years | 48.4% |
Market Capitalization | 114.2B |
Book Value | $14.67 |
Dividend Share | 3.04 |
Dividend Yield | 3.41% |
Earnings Per Share (EPS) | 0.83 |
PE Ratio | 110.47 |
PEG Ratio | 0.53 |
Wall Street Target Price | 87.58 |
Profit Margin | 3.79% |
Operating Margin TTM | 38.72% |
Return On Assets TTM | 11.55% |
Return On Equity TTM | 5.26% |
Revenue TTM | 27.8B |
Revenue Per Share TTM | 22.3 |
Quarterly Revenue Growth YOY | 5.4% |
Gross Profit TTM | 21.6B |
EBITDA | 13.5B |
Diluted Eps TTM | 0.83 |
Quarterly Earnings Growth YOY | 0.55 |
EPS Estimate Current Year | 3.81 |
EPS Estimate Next Year | 7.25 |
EPS Estimate Current Quarter | 1.6 |
EPS Estimate Next Quarter | 1.74 |
What analysts predicted
Downside of 10.54%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 22.1B | ↓ 15.24% |
Net Income | 5.5B | ↑ 17.87% |
Net Profit Margin | 24.65% | ↑ 6.92% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 22.4B | ↑ 1.46% |
Net Income | 5.4B | ↓ 1.26% |
Net Profit Margin | 23.99% | ↓ 0.66% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 24.7B | ↑ 9.98% |
Net Income | 89.0M | ↓ 98.35% |
Net Profit Margin | 0.36% | ↓ 23.63% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 27.3B | ↑ 10.6% |
Net Income | 6.2B | ↑ 6894.38% |
Net Profit Margin | 22.8% | ↑ 22.44% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.3B | ↓ 0.09% |
Net Income | 4.6B | ↓ 26.23% |
Net Profit Margin | 16.83% | ↓ 5.97% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 27.1B | ↓ 0.6% |
Net Income | 5.7B | ↑ 23.37% |
Net Profit Margin | 20.89% | ↑ 4.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.4B | ↓ 14.03% |
Net Income | 1.0B | ↓ 38.41% |
Net Profit Margin | 15.9% | ↓ 6.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.6B | ↑ 3.89% |
Net Income | 1.0B | ↑ 3.47% |
Net Profit Margin | 15.84% | ↓ 0.06% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.1B | ↑ 6.83% |
Net Income | 2.2B | ↑ 108.61% |
Net Profit Margin | 30.92% | ↑ 15.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.1B | ↑ 0.92% |
Net Income | 1.4B | ↓ 34.45% |
Net Profit Margin | 20.08% | ↓ 10.84% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 6.7B | ↓ 6.03% |
Net Income | -4.2B | ↓ 391.81% |
Net Profit Margin | -62.37% | ↓ 82.45% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 6.9B | ↑ 3.93% |
Net Income | 1.6B | ↓ 138.71% |
Net Profit Margin | 23.23% | ↑ 85.6% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 63.7B | ↓ 9.4% |
Total Liabilities | 42.1B | ↓ 15.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 61.6B | ↓ 3.22% |
Total Liabilities | 39.0B | ↓ 7.51% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 68.4B | ↑ 11.0% |
Total Liabilities | 50.2B | ↑ 28.76% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 68.0B | ↓ 0.67% |
Total Liabilities | 46.9B | ↓ 6.57% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 63.2B | ↓ 7.04% |
Total Liabilities | 42.0B | ↓ 10.51% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 62.1B | ↓ 1.66% |
Total Liabilities | 39.4B | ↓ 6.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 61.9B | ↓ 2.05% |
Total Liabilities | 40.9B | ↓ 2.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.3B | ↑ 0.75% |
Total Liabilities | 41.2B | ↑ 0.75% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.4B | ↑ 0.06% |
Total Liabilities | 40.1B | ↓ 2.7% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 62.1B | ↓ 0.4% |
Total Liabilities | 39.4B | ↓ 1.88% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 56.3B | ↓ 9.39% |
Total Liabilities | 38.8B | ↓ 1.37% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 53.6B | ↓ 4.82% |
Total Liabilities | 35.4B | ↓ 8.89% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4B | ↓ 29.4% |
Investing Cash Flow | 14.4B | ↓ 189.33% |
Financing Cash Flow | -12.3B | ↓ 463.04% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.1B | ↑ 8.86% |
Investing Cash Flow | -7.8B | ↓ 154.45% |
Financing Cash Flow | -7.6B | ↓ 38.03% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.2B | ↓ 10.67% |
Investing Cash Flow | -14.6B | ↑ 86.96% |
Financing Cash Flow | 770.0M | ↓ 110.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.4B | ↑ 39.37% |
Investing Cash Flow | -3.1B | ↓ 78.58% |
Financing Cash Flow | -8.9B | ↓ 1252.86% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.1B | ↓ 20.31% |
Investing Cash Flow | -2.5B | ↓ 21.24% |
Financing Cash Flow | -6.5B | ↓ 27.13% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.0B | ↓ 11.75% |
Investing Cash Flow | -2.3B | ↓ 8.15% |
Financing Cash Flow | -5.1B | ↓ 20.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.7B | ↓ 32.03% |
Investing Cash Flow | -826.0M | ↑ 120.27% |
Financing Cash Flow | -1.4B | ↓ 9.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.3B | ↑ 34.0% |
Investing Cash Flow | -483.0M | ↓ 41.53% |
Financing Cash Flow | -1.1B | ↓ 21.69% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 24.86% |
Investing Cash Flow | -229.0M | ↓ 52.59% |
Financing Cash Flow | -1.5B | ↑ 37.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↑ 23.52% |
Investing Cash Flow | -727.0M | ↑ 217.47% |
Financing Cash Flow | -1.1B | ↓ 27.6% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↑ 2.31% |
Investing Cash Flow | -2.2B | ↑ 203.58% |
Financing Cash Flow | -1.4B | ↑ 23.84% |
Sell
Neutral
Buy
Gilead Sciences Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Gilead Sciences Inc. | 14.89% | 50.8% | 25.67% | 48.4% | 49.74% |
Eli Lilly And Company | -12.72% | 2.9% | 28.8% | 206.09% | 602.41% |
Johnson & Johnson | -1.85% | 5.22% | 4.24% | -3.77% | 17.84% |
Merck & Co. Inc. | -6.77% | -21.91% | -3.09% | 22.36% | 21.03% |
Novo Nordisk A/s | -8.17% | -15.04% | 5.77% | 87.67% | 271.97% |
Abbvie Inc | 3.89% | 24.97% | 41.17% | 72.76% | 135.31% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc. | 110.47 | 110.47 | 0.53 | 3.81 | 0.05 | 0.12 | 0.03 | 14.67 |
Eli Lilly And Company | 86.94 | 86.94 | 0.76 | 13.18 | 0.65 | 0.14 | 0.01 | 15.83 |
Johnson & Johnson | 26.18 | 26.18 | 0.94 | 9.95 | 0.21 | 0.08 | 0.03 | 29.14 |
Merck & Co. Inc. | 21.3 | 21.3 | 0.07 | 7.75 | 0.33 | 0.11 | 0.03 | 17.19 |
Novo Nordisk A/s | 33.88 | 33.88 | 1.68 | 3.37 | 0.89 | 0.23 | 0.01 | 23.9 |
Abbvie Inc | 70.35 | 70.35 | 0.48 | 10.94 | 0.54 | 0.08 | 0.03 | 3.84 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Gilead Sciences Inc. | Hold | $114.2B | 49.74% | 110.47 | 3.79% |
Eli Lilly And Company | Buy | $737.0B | 602.41% | 86.94 | 20.48% |
Johnson & Johnson | Buy | $380.1B | 17.84% | 26.18 | 16.74% |
Merck & Co. Inc. | Buy | $255.3B | 21.03% | 21.3 | 19.23% |
Novo Nordisk A/s | Buy | $483.6B | 271.97% | 33.88 | 34.84% |
Abbvie Inc | Buy | $355.5B | 135.31% | 70.35 | 9.22% |
BlackRock Inc
Vanguard Group Inc
Capital World Investors
Capital Research Global Investors
State Street Corp
Morgan Stanley - Brokerage Accounts
In the quarter ending March,2024. Gilead Sciences Inc. has declared dividend of $0.77
Read MoreGilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Organization | Gilead Sciences Inc. |
Employees | 18000 |
CEO | Mr. Daniel P. O'Day |
Industry | Health Technology |
Spdr Portfolio Large Cap Etf
$97.90
+6.77%
Evergy, Inc
$97.90
+6.77%
Pnc Financial Services Group, Inc.
$97.90
+6.77%
The Cigna Corp
$97.90
+6.77%
The Walt Disney Company
$97.90
+6.77%
Caterpillar Inc.
$97.90
+6.77%
Textron Inc.
$97.90
+6.77%
Canadian National Railway Company
$97.90
+6.77%
Spdr Portfolio Long Term Treasury Etf
$97.90
+6.77%